Grimberg D, Tarrade T, Deschamps de Paillette E
Hôpital Tenon, Paris.
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:109-12.
The antihypertensive effectiveness and the clinical and biochemical safety of cicletanine were evaluated in 84 patients (28 women, 56 men) presenting with permanent essential hypertension without severe cardiovascular complications. The hypertension was insufficiently controlled by a beta-blocker, a centrally acting antihypertensive drug or nifedipine. After 3 months of treatment during which cicletanine was added to each of these three classes of drugs, there was a significant fall of systolic arterial pressure (-18 mmHg with beta-blockers, -17 mmHg with central agents and -26 mmHg with nifedipine) and diastolic arterial pressure (-22, -21 and -28 mmHg respectively), resulting in normalization of blood pressure (less than 160/95 mmHg) in 63%, 43% and 50% respectively of patients in each therapeutic group. The fall of blood pressure was accompanied by a significant decrease of functional symptoms (headache, palpitations, dizziness); in the nifedipine group, the addition of cicletanine resulted in complete regression of anginal attacks. The therapeutic combinations were well tolerated; only two patients were excluded from the study for undesirable effects unascribable to cicletanine. Otherwise, the side-effects observed were minor. The biochemical values measured did not significantly vary, and the variations noted were of small amplitude.
在84例（28例女性，56例男性）患有持续性原发性高血压且无严重心血管并发症的患者中，评估了环戊噻嗪的降压效果以及临床和生化安全性。这些患者的高血压通过β受体阻滞剂、中枢性抗高血压药物或硝苯地平控制不佳。在将环戊噻嗪添加到这三类药物中的每一种进行3个月治疗后，收缩压显著下降（使用β受体阻滞剂时下降18 mmHg，使用中枢性药物时下降17 mmHg，使用硝苯地平时下降26 mmHg），舒张压也分别下降（分别为22、21和28 mmHg），各治疗组分别有63%、43%和50%的患者血压恢复正常（低于160/95 mmHg）。血压下降伴随着功能性症状（头痛、心悸、头晕）的显著减轻；在硝苯地平组中，添加环戊噻嗪导致心绞痛发作完全缓解。这些治疗组合耐受性良好；只有两名患者因与环戊噻嗪无关的不良影响而被排除在研究之外。否则，观察到的副作用较小。所测量的生化值没有显著变化，且所记录的变化幅度较小。
